Dr. Benjamin Levy from Johns Hopkins led a comprehensive peer exchange with thoracic oncologists Drs. Ross Camidge, Julia Rotow, Siddhartha Devarakonda, and Gilberto Lopes discussing the evolving landscape of EGFR-mutant advanced non-small cell lung cancer treatment post-ELCC 2026. The program addressed the transformation from simple osimertinib monotherapy to complex decision-making involving three frontline options: osimertinib alone, FLAURA-2 (osimertinib plus chemotherapy), and MARIPOSA (osimertinib plus amivantamab). Key discussions centered on risk stratification using TP53 mutations, CNS disease, and ctDNA levels to guide treatment intensification decisions. Second-line strategies comparing COMPEL versus MARIPOSA-2 regimens highlighted ongoing challenges in sequencing therapies. The panel explored subcutaneous amivantamab's impact on tolerability, emerging resistance mechanisms including MET amplification, and the role of antibody-drug conjugates like datopotamab deruxtecan. Patient-reported outcomes, shared decision-making, and personalized approaches based on molecular profiling emerged as critical themes. The discussion emphasized balancing efficacy gains with quality of life considerations while advancing toward cure through novel combinations and resistance prevention strategies.
Dr. Benjamin Levy introduces an expert panel to discuss the increasingly complex landscape of EGFR-mutant advanced non-small cell lung cancer (NSCLC) treatment. The frontline setting now includes three viable options representing a significant shift from the previously straightforward osimertinib monotherapy approach.
Dr. Julia Rotow emphasizes shared decision-making as essential for frontline treatment selection, noting the dramatic shift from osimertinib monotherapy as standard to combination therapy as default over the past 2 to 3 years. Treatment decisions require balancing disease-associated risk factors with patient-specific considerations.
The panel contrasts FLAURA-2 (osimertinib plus chemotherapy) with MARIPOSA (osimertinib plus amivantamab), acknowledging similar efficacy profiles with overall survival approaching four years in both regimens. However, significant differences exist in toxicity profiles and supportive care requirements.
Dr. Rotow discusses limitations of traditional CTCAE toxicity grading for capturing patient experiences with EGFR-targeted therapies. Although useful for discrete, measurable, and life-threatening toxicities, CTCAE poorly captures lower-grade effects like skin rash or fatigue that significantly impact quality of life over extended treatment periods.
The FDA approval of subcutaneous amivantamab with monthly dosing represents a significant advancement in treatment convenience. Dr. Devarakonda emphasizes that while toxicity concerns shouldn't discourage effective regimen use, practical barriers including time and supportive care requirements make subcutaneous administration valuable.
TP53 mutations occur in over 50% of patients with EGFR-mutant lung cancer, representing a consistently negative prognostic factor. Dr. Rotow explains that TP53 mutations appear prominently on NGS reports, requiring clinicians to determine appropriate management strategies.
At disease progression, comprehensive tumor characterization becomes as important as initial diagnosis. Dr. Camidge argues against using regimens that don't require resistance mechanism identification, emphasizing that understanding heterogeneous resistance mechanisms guides optimal therapy selection.
Following osimertinib monotherapy progression without CNS involvement, clinicians choose between COMPEL (continuing osimertinib plus chemotherapy) and MARIPOSA-2 (amivantamab plus chemotherapy without osimertinib continuation).
The most challenging scenario involves patients who received frontline chemotherapy-osimertinib combinations and subsequently progress. Dr. Camidge reviews subgroup data from FLAURA-2 showing that approximately 70% of progressive patients received subsequent chemotherapy, with differences based on prior platinum exposure.
MET pathway involvement in EGFR resistance varies by initial treatment regimen. Dr. Devarakonda explains that MET amplification represents the most common known resistance mechanism following osimertinib-chemotherapy combinations, allowing EGFR blockade bypass.
The panel presents individual sequencing strategies for EGFR-mutant advanced NSCLC. Dr. Camidge favors modified FLAURA-2 approaches, starting osimertinib monotherapy to establish patient relationships and toxicity tolerance before adding platinum-pemetrexed within 6 weeks unless contraindicated. Approximately 20% of his generally fit Denver population receives osimertinib monotherapy.
Dr. Camidge predicts TROP2-directed ADCs will become obsolete due to poor tolerability profiles, while better-tolerated ADC platforms will emerge. He anticipates advances in understanding persistent cell populations preventing complete tumor eradication, potentially through surface marker-directed ADCs or radiopharmaceuticals. Pleural-based therapies represent another frontier, given recurrent pleural involvement in EGFR-mutant disease.
